Susanne Muehlbauer

Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial

Luca Gianni, Urania Dafni, Richard D. Gelber et al. · The Lancet Oncology · 2011 · 611 citations

Breast Oncology, Oncology, Adjuvant Chemotherapy +5

Trastuzumab-Associated Cardiac Adverse Effects in the Herceptin Adjuvant Trial

Thomas Suter, Marion Procter, Dirk J. van Veldhuisen et al. · Journal of Clinical Oncology · 2007 · 563 citations · Full text

Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I–III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial

Gustavo Ismael, Roberto Hegg, Susanne Muehlbauer et al. · The Lancet Oncology · 2012 · 337 citations

Hannah Study, Breast Oncology, Oncology +6

Longer-Term Assessment of Trastuzumab-Related Cardiac Adverse Events in the Herceptin Adjuvant (HERA) Trial

Marion Procter, Thomas Suter, Evandro de Azambuja et al. · Journal of Clinical Oncology · 2010 · 244 citations

Idasanutlin Plus Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia: Results of the MIRROS Trial

Marina Konopleva, Christoph Röllig, Jamie Cavenagh et al. · Blood Advances · 2022 · 68 citations · Full text